Last updated: February 16, 2026
Market Overview
NDC 00004-0802 is marketed as Nivolumab, a monoclonal antibody targeting PD-1, developed by Bristol-Myers Squibb (BMS). It is approved primarily for several cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. The drug's broad approval and strong clinical profile position it as a leading immunotherapy product.
Market Size and Growth Drivers
Current Market Size (2022):
The global oncology immunotherapy market was valued at approximately $75 billion, with checkpoint inhibitors like Nivolumab representing a significant segment. Nivolumab accounts for roughly 30% of the checkpoint inhibitor revenue, translating to an estimated $22.5 billion in 2022.
Projected Market Growth:
The immunotherapy segment is expected to grow at a compound annual growth rate (CAGR) of 11-13% through 2030, driven by expanded indications, combination therapies, and new approvals.
Competitive Landscape
Key Competitors:
- Pembrolizumab (Keytruda, Merck)
- Atezolizumab (Tecentriq, Roche)
- Durvalumab (Imfinzi, AstraZeneca)
| Market Share Distribution (2022): |
Product |
Estimated Revenue |
Market Share |
| Nivolumab |
$6.5 billion |
29% |
| Pembrolizumab |
$8.1 billion |
36% |
| Atezolizumab |
$3.2 billion |
14% |
| Durvalumab |
$2.7 billion |
12% |
Pricing and Revenue Trends
List Price:
For approved indications in the US, the average wholesale price (AWP) for Nivolumab is approximately $7,500 per 100 mg vial. Dosing varies based on indication and patient weight but generally ranges from 240 mg to 480 mg per administration, typically every two weeks.
Per-Patient Cost:
Average annual treatment cost ranges between $100,000 and $150,000 per patient, varying with dosage and duration.
Revenue Trends:
BMS revenue from Nivolumab increased by approximately 10% annually from 2018-2022. Key drivers include expanding indications and combination regimens, such as nivolumab plus ipilimumab or chemotherapy.
Price Projections (2023-2030)
| Year |
Estimated Average Price (per dose) |
Expected Revenue (BMS) |
Market Share Projections |
| 2023 |
$7,500 |
$6.8 billion |
Maintains ~29% of checkpoint inhibitor revenue |
| 2024 |
$7,600 |
$7.3 billion |
Slight increase due to new indications |
| 2025 |
$7,700 |
$8.0 billion |
Launch of biosimilars in select markets may impact pricing |
| 2026 |
$7,900 |
$8.5 billion |
Biosimilar competition begins affecting pricing strategies |
| 2027 |
$8,100 |
$9.0 billion |
Market shift may drive down average price by ~5% globally |
| 2028 |
$8,200 |
$9.3 billion |
Steady growth driven by new indications and combination therapies |
| 2029 |
$8,400 |
$9.8 billion |
Increased biosimilar competition in Europe and Asia |
| 2030 |
$8,500 |
$10.1 billion |
Price stabilization expected post-biosimilar entry |
Biosimilar Impact
Biosimilar versions of nivolumab are in development in multiple regions, with the first entries expected in the United States and Europe around 2025-2026. These biosimilars could reduce the price of nivolumab by approximately 20-30%, pressuring incumbent pricing and revenue.
Regional Market Dynamics
- United States: Dominant market, high reimbursement rates, price regulation.
- Europe: Growing biosimilar adoption, growing at CAGR of 12-14%.
- Asia-Pacific: Rapid market expansion, increasing healthcare spending, less biosimilar penetration initially but gaining ground.
Regulatory and Policy Factors
- Price negotiations with CMS and private insurers in the US influence net revenues.
- Internationally, pricing varies based on government regulation.
- Patent expiry in the US is expected around 2028-2029, opening opportunities for biosimilar competition.
Key Takeaways
- Nivolumab remains a leading immune checkpoint inhibitor, with a global market share of approximately 29% among comparators.
- The drug’s revenue is projected to reach over $10 billion annually by 2030, with moderate price growth offset by biosimilar competition.
- Pricing per dose is around $7,500, with annual patient treatment costs approaching $150,000.
- Biosimilar entries, starting circa 2025, are expected to reduce prices and pressure revenues.
- Regional dynamics significantly influence overall market trends, with the US maintaining dominant sales volume despite regulatory constraints.
FAQs
1. What are the main indications for Nivolumab?
Nivolumab is approved for melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, and several other cancers.
2. How does the price of Nivolumab compare with similar drugs?
It is comparable, with average wholesale prices around $7,500 per 100 mg vial, similar to Pembrolizumab. Prices are influenced by indication, dosing, and reimbursement policies.
3. When are biosimilars expected to enter the market?
In the US and Europe, biosimilars are projected to launch around 2025–2026, potentially reducing prices by 20–30%.
4. How might biosimilar competition affect future revenues?
Biosimilars likely will reduce revenue growth rates and may lead to a decline in overall sales volumes over time, depending on market adoption and pricing.
5. What are the key regional factors influencing Nivolumab’s market?
Pricing and reimbursement policies, healthcare spending, and biosimilar entry timelines are primary influencers, with the US leading in revenue but facing more regulation, while emerging markets show rapid expansion potential.
References
[1] Bloomberg, “Global Oncology Immunotherapy Market Size & Forecast,” 2022.
[2] Bristol-Myers Squibb, “Nivolumab (Opdivo) Product Details,” 2023.
[3] IQVIA, “Market Trends in Oncology Drugs,” 2022.
[4] GlobalData, “Biosimilar Outlook for Checkpoint Inhibitors,” 2023.
